{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:06:17Z","timestamp":1791266777098,"version":"4.1.0"},"reference-count":41,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,10,13]],"date-time":"2011-10-13T00:00:00Z","timestamp":1318464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:p>\n                    <jats:bold>Abstract:\u2002<\/jats:bold>\n                    Lindane is an organochloride pesticide, first introduced as a scabicide for human use in the 1950s (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#b1\">1<\/jats:ext-link>\n                    ). Because of its low cost and efficacy, it quickly became a first\u2010line treatment for scabies and head lice, but not long after its use became widespread, its safety was called into question, primarily regarding its neurotoxic effects. We intend to show through review of the literature and databases that lindane has been associated with numerous severe and fatal adverse reactions. This review will summarize 67 cases of adverse reactions and deaths associated with the medical use of lindane. Many of the most serious events and fatalities occurred in pediatric and geriatric populations. We concede that toxicity frequently arises from misuse, but labeled usage of lindane caused 43% of the serious adverse reactions of this review. Moreover, the numerous instances of lindane misuse elucidate the importance of clear labeling and instructions, especially with a product with a narrow therapeutic index. Therefore, this report attempts to elucidate the dangers of lindane as a medical treatment for scabies and head lice by providing a comprehensive review of all documented adverse drug reactions since its introduction.\n                  <\/jats:p>","DOI":"10.1111\/j.1525-1470.2011.01519.x","type":"journal-article","created":{"date-parts":[[2011,10,13]],"date-time":"2011-10-13T08:29:10Z","timestamp":1318494550000},"page":"141-146","source":"Crossref","is-referenced-by-count":112,"title":["Lindane Toxicity: A Comprehensive Review of the Medical Literature"],"prefix":"10.1111","volume":"29","author":[{"given":"Katherine","family":"Nolan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Kamrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Levitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,10,13]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1977.01640030099018"},{"key":"e_1_2_7_3_2","first-page":"1447","article-title":"Concerns over lindane treatment for scabies and lice","volume":"168","author":"Wooltorton E","year":"2003","journal-title":"CMAJ"},{"key":"e_1_2_7_4_2","volume-title":"Therapeutic Drugs","author":"Dollery C","year":"1999"},{"key":"e_1_2_7_5_2","unstructured":"US Environmental Protection Agency.Lindane; Cancellation Order.2006. Available at:http:\/\/www.epa.gov\/fedrgstr\/EPA\u2010PEST\/2006\/December\/Day\u201013\/p21101.htm. Accessed on October 24 2010."},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.10668"},{"key":"e_1_2_7_7_2","unstructured":"Michigan Legislature\u2010 House Bill 4402. 2009. Available:http:\/\/www.legislature.mi.gov\/(S(oggldiaj4ix2m055yz2etn45))\/mileg.aspx?page=getObject&objectName=2009\u2010HB\u20104402. Accessed on October 30 2010."},{"key":"e_1_2_7_8_2","unstructured":"US Food and Drug Administration (FDA).Lindane Assessment Memorandum.2003. Available:http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/UCM110853.pdf. Accessed on October 25 2010."},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000079899"},{"key":"e_1_2_7_10_2","unstructured":"Food and Drug Administration.Warning Letter. Available at:http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/EnforcementActivitiesbyFDA\/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies\/ucm054144.pdf. Accessed on February 4 2011."},{"key":"e_1_2_7_11_2","first-page":"582","article-title":"Serious poisoning by hexachlorocyclohexane","volume":"8","author":"Danopoulos E","year":"1953","journal-title":"Arch Indiist Hyg Chicago"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1983.01650260050017"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.2.220"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1039\/c0em00110d"},{"key":"e_1_2_7_15_2","unstructured":"United States Environmental Protection Agency.Basic information about lindane in drinking water. Available at:http:\/\/water.epa.gov\/drink\/contaminants\/basicinformation\/lindane.cfm#four. Updated June 14 2010; Accessed on October 24 2010."},{"key":"e_1_2_7_16_2","unstructured":"Health Canada.Canada Vigilance Adverse Reaction Database. Available at:http:\/\/www.hc\u2010sc.gc.ca\/dhp\u2010mps\/medeff\/databasdon\/index\u2010eng.php. Updated November 16 2010; Accessed on February 9 2011."},{"key":"e_1_2_7_17_2","unstructured":"Center for Drug Evaluation and Research US Food and Drug Administration.FDA public health advisory: safety of topical lindane products for the treatment of scabies and lice. Rockville (MD)2003. Available at:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm110845.htm. Accessed on October 25 2010."},{"key":"e_1_2_7_18_2","unstructured":"Lindane lotion USP 1% prescribing information. Updated March 28 2003. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/006309lotionlbl.pdf. Accessed on October 25 2010."},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.82.6.857"},{"key":"e_1_2_7_20_2","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1001\/archinte.1990.00390220125026","article-title":"Lindane (Kwell)\u2010induced aplastic anemia","volume":"150","author":"Rauch AE","year":"1990","journal-title":"Arch Intern Med"},{"key":"e_1_2_7_21_2","first-page":"533","article-title":"Unintentional topical lindane ingestions\u2014United States, 1998\u20132003","volume":"54","author":"Centers for Disease Control and Prevention (CDC)","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7005.604"},{"key":"e_1_2_7_23_2","first-page":"715","article-title":"Malathion for head lice and scabies: treatment and safety considerations","volume":"8","author":"Idriss S","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_24_2","unstructured":"US Food and Drug Administration.FDA Approves Benzyl Alcohol Lotion for the Treatment of Head Lice.2009.http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm149562.htm. Accessed on February 10 2011."},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-3762"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2009.01059.x"},{"key":"e_1_2_7_27_2","first-page":"CD000320","article-title":"Interventions for treating scabies","volume":"3","author":"Strong M","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(95)70020-X"},{"key":"e_1_2_7_29_2","unstructured":"Appleby J. FDA cites toxic risk of popular head\u2010lice drug. USA Today. 2008 Jan."},{"key":"e_1_2_7_30_2","first-page":"125","article-title":"Untoward effects associated with lindane abuse","volume":"141","author":"Berry DH","year":"1987","journal-title":"Am J Dis Child"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(94)70215-2"},{"key":"e_1_2_7_32_2","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/archderm.1987.01660320098020","article-title":"Lindane neurotoxic reaction in nonbullous congenital ichthyosiform erythroderma","volume":"123","author":"Friedman SJ","year":"1987","journal-title":"Arch Dermatol"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(99)71191-6"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1980.23"},{"key":"e_1_2_7_35_2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1542\/peds.59.4.643","article-title":"Scabies: transcutaneous poisoning during treatment","volume":"59","author":"Lee B","year":"1977","journal-title":"Pediatrics"},{"key":"e_1_2_7_36_2","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1001\/jama.1976.03270260012008","article-title":"Suspected reactions to gamma benzene hexachloride","volume":"25","author":"Lee B","year":"1976","journal-title":"JAMA"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(81)80095-3"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0736-4679(99)00162-6"},{"key":"e_1_2_7_39_2","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/archderm.1979.04010100044018","article-title":"Transcutaneous gamma benzene hexachloride absorption and toxicity in infants and children","volume":"115","author":"Pramanik AK","year":"1979","journal-title":"Arch Dermatol"},{"key":"e_1_2_7_40_2","first-page":"662","article-title":"Acute intoxication with lindane (gamma benzene hexachloride)","volume":"6","author":"Telch J","year":"1982","journal-title":"Can Med Assoc J"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1991.tb02906.x"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.3200\/AEOH.62.4.201-203"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1525-1470.2011.01519.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1525-1470.2011.01519.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T20:49:14Z","timestamp":1698612554000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1525-1470.2011.01519.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,13]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1111\/j.1525-1470.2011.01519.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1525-1470.2011.01519.x","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,13]]}}}